Novocure Limited (NVCR) - News Archive

As the fight against pancreatic cancer continues, Novocure Limited (NASDAQ: NVCR) has made significant strides in its development of Tumor Treating Fields (TTFields) therapy. The company announced that results from the...

Revolutionizing Cancer Treatment: Optune Lua Receives CE Mark for Advanced NSCLC Therapy In a significant stride toward the advancement of cancer treatment technologies, Novocure (NASDAQ: NVCR), a global oncology compan...

In recent years, the landscape of oncology has seen remarkable advances, particularly in innovative therapeutic approaches aimed at treating challenging cancer types. Novocure, a pioneering company in the development of...

FDA Approves Novocure s Optune Lua: A New Hope for Patients with Metastatic Non-Small Cell Lung Cancer In a significant development for oncology, Novocure (NASDAQ: NVCR) announced that the U.S. Food and Drug Administrat...

In a significant advance in cancer therapeutics, Novocure (NASDAQ: NVCR), a pioneering company in cancer treatment technologies, has received the green light from the U.S. Food and Drug Administration (FDA) for its inno...

Metis Phase 3 Clinical Trial Demonstrates Significant Progress in Delaying Brain Metastasis with Improved Quality of Life, as Novocure Releases Promising Data at ASCO 2024ROOT, Switzerland - Novocure (NASDAQ: NVCR) has...

William Doyle, Novocure s Executive Chairman, lauded the company s strong execution during the first quarter. The company achieved an 11% increase in active patients with glioblastoma (GBM), a highly malignant brain can...

Novocure, a leading global oncology company specializing in cancer treatment, has announced that the results of its METIS phase 3 clinical trial will be presented as a late-breaking abstract at the 2024 American Society...

Novocure s METIS Phase-3 Clinical Trial for Non-Small-Cell Lung Cancer (NSCLC) has achieved its primary endpoint, signifying a statistical improvement in the time until intracranial progression in adult patients with 1-...

Novocure, a leading oncology company, has recently announced a breakthrough in their phase 3 METIS clinical trial. The trial has shown a significant extension in the time to intracranial progression for patients with br...

Biomedical firm Novocure (NASDAQ: NVCR) has announced the U.S. Food and Drug Administration’s (FDA) acceptance for filing of its Premarket Approval (PMA) application. The PMA is focused on procuring authorization for th...

Novocure s Optune Gio Shows Promise in Phase 3 TRIDENT Trial for Newly Diagnosed Glioblastoma PatientsIn a groundbreaking development in the fight against glioblastoma (GBM), Novocure, a Swiss-based global oncology comp...

Novocure, a leading global oncology company, has recently named Dr. Nicolas Leupin as their new Chief Medical Officer (CMO). Dr. Leupin s appointment comes at a crucial time for the company as it seeks to navigate both...

Novocure is set to make significant presentations on its Tumor Treating Fields (TTFields) therapy, which includes new clinical data and real-world evidence. The research will be unveiled at the 2023 Society for Neuro-On...